TNFRSF1A and sarcopenia: From the psoas muscle Hi-C dataset we identified unique druggable eGenes (e.g., GRID1, TNFRSF1A, STAT4) which represent potential therapeutic targets for treating the muscle wasting/weakness symptoms associated with NMD and sarcopenia.